Reporting from ESMO Virtual Congress 2020, Olivier Mir comments on potential therapeutic options in rare forms of Sarcomas.
He reports on the activity of regorafenib in metastatic relapsed Ewing Sarcoma, and shows interesting results from pembrolizumab in a cohort of patients with none of the potential biomarkers for this drug.
Abstracts:
- LBA68 - Results of the randomized, Placebo (PL)-controlled Phase II study evaluating the efficacy and safety of Regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma, on behalf of the French Sarcoma Group (FSG) and Unicancer
- 1619O - High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study